NCT05295121View on ClinicalTrials.gov

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

February 22, 2022

Study Completion Date

March 17, 2022

Conditions
Healthy
Interventions
DRUG

XC221 100 mg tablets

XC221, 3 discrete doses separated by 7-day wash-out periods

Trial Locations (1)

196143

"Limited Liability Company Research Center Eco-Safety", Saint Petersburg

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY